AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26267747
Drug: Liposomal prostaglandin
RxNorm normalized name: Liposomal prostaglandin E1
DrugBank: Liposomal prostaglandin E1 (DB05391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal prostaglandin E1 (lipo‐PGE1) 20 μg/day diluted in 10 ml of normal saline, administered intravenously over 5 min starting 3 days before PCI and continuing for 4 days after PCI
Trial: 26267747
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (normal saline 10 ml administered intravenously)
Trial: 25055027
Drug: NAP SACC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAP SACC program (treatment group)
Trial: 21777507
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate (PP): 50 mg eq. on days 1 and 8, flexible dosing 25-100 mg eq. once-monthly
Trial: 21777507
Drug: Risperidone long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone long-acting injectable (RIS-LAI): bi-weekly injections of 25 mg on days 8 and 22, flexible dosing (25-50 mg) starting from day 36
Trial: 21777507
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (PP and RIS-LAI)
Trial: 19476477
Drug: Inhaled TI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled TI (25 U)
Trial: 19476477
Drug: Inhaled TI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled TI (50 U)
Trial: 19476477
Drug: Inhaled TI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled TI (100 U)
Trial: 19476477
Drug: Subcutaneous RHI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous RHI (10 IU)
Trial: 15051600
Drug: High-oleate meal
RxNorm normalized name: oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-oleate meal (50 g fat)
Trial: 15051600
Drug: High-palmitate meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-palmitate meal (50 g fat)
Trial: 15051600
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (15 g fat)
Trial: 12113542
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (chewed three times a day from the first postoperative AM until oral intake)
Trial: 9728846
Drug: Acetated Ringer's
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer's solution during isoflurane anesthesia
Trial: 2491990
Drug: Short-term administration
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term administration of Buserelin (day 1)
Trial: 1120556
Drug: Perexiline maleate
RxNorm normalized name: perhexiline
DrugBank: Perhexiline (DB01074)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perexiline maleate at 400 mg/die
Trial: 1120556
Drug: Prenilamine at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenilamine at 120 mg/die
Trial: 30102427
Drug: BUP/SAM 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP/SAM 2 mg/2 mg
Trial: 30102427
Drug: BUP/SAM at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUP/SAM at 4-fold (8 mg/8 mg) and 8-fold (16 mg/16 mg) the therapeutic dose
Trial: 30102427
Drug: Buprenorphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine alone (8 mg and 16 mg)
Trial: 29045326
Drug: Strawberry (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry (25 g freeze-dried strawberries)
Trial: 21206932
Drug: NitrAdine tablets
RxNorm normalized name: Nitrocine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NitrAdine tablets
Trial: 15548480
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g mucuna preparation
Trial: 11305824
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% with epinephrine 1:200,000 infiltrations (10 ml into the portals, 10 ml at the medial tibial incision site, 10 ml at the lateral femoral incision site, and 10 ml intra-articularly presurgically; 5 ml at the medial tibial incision and 10 ml at the lateral femoral incision postsurgically)
Trial: 11305824
Drug: Saline 0.9%
RxNorm normalized name: CVS Saline 0.9% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.9% infiltrations (same administration as treatment group)
Trial: 9158385
Drug: Trimetazidine treatment
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine treatment started twenty-four hours after percutaneous transluminal coronary angioplasty (PTCA) in 26 patients (Group I)
Trial: 9158385
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without trimetazidine treatment (25 patients, Group II)
Trial: 2437347
Drug: Dextran sulfate
RxNorm normalized name: dextran sulfate
DrugBank: Dextran (DB09255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran sulfate (mild anticoagulant) for 7 to 56 months (average, 25.4 months)
Trial: 27421623
Drug: Low-dose fluocinolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose fluocinolone acetonide implant (FAi)
Trial: 27421623
Drug: High-dose fluocinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose fluocinolone acetonide implant (FAi)
Trial: 27421623
Drug: Fluocinolone acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone acetonide implant (FAi)
Trial: 25042693
Drug: Sildenafil (20mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (20mg 3× daily)
Trial: 18277899
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) for steroid-dependent CD patients
Trial: 11967597
Drug: Selective decontamination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective decontamination of subglottic area (SDSA) using a continuous infusion of a suspension containing polymyxin, tombramycin, and amphotericin B (n=30)
Trial: 9989716
Drug: Low-dose hydrocortisone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose hydrocortisone (5 mg or 10 mg daily) for 1 month
Trial: 8528370
Drug: Tacrine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrine treatment for 14 months
Trial: 24130358
Drug: Salsalate 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salsalate 3.5 g/day
Trial: 15982963
Drug: Out-of-Program service
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-of-Program service contact Days (OD) during Treatment (DT)
Trial: 15982963
Drug: Out-of-Program services
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-of-Program services between 3 and 9 months post-treatment
Trial: 11728816
Drug: Apocynin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apocynin (3 ml of 0.5 mg/ml) inhaled 2 times before and 6 times after O(3) exposure
Trial: 3350281
Drug: Cimetidine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (600 mg twice daily)
Trial: 24099637
Drug: Levodopa (L-Dopa;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa (L-Dopa; 100 mg)
Trial: 22562746
Drug: Daily undulating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily undulating periodization (DUP)
Trial: 19373103
Drug: Very deep
RxNorm normalized name: HOMOSALATE 5 g in 100 mL / OCTINOXATE 6.5 g in 100 mL / OXYBENZONE 1.2 g in 100 mL TOPICAL CREAM [Mary Kay CC Cream Sunscreen Broad Spectrum SPF 15 Very Deep]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very deep sclerectomy with collagen implant (VDSCI)
Trial: 18835931
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion (25 ng . kg(‐1) . min(‐1))
Trial: 15043569
Drug: 100 microg
RxNorm normalized name: Digoxin 100 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 microg lenograstim daily
Trial: 15043569
Drug: 250 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 microg lenograstim daily
Trial: 11355564
Drug: Triple-dose albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple-dose albendazole (400 mg for 3 consecutive days) plus praziquantel (40 mg/kg) plus iron supplementation (ferrous fumarate 200 mg weekly for 10 weeks)
Trial: 11355564
Drug: Single-dose albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose albendazole (400 mg) plus praziquantel (40 mg/kg)
Trial: 11355564
Drug: Triple-dose albendazole
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple-dose albendazole (400 mg for 3 consecutive days) plus praziquantel (40 mg/kg)
Trial: 11355564
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no anthelmintic treatment)
Trial: 11355564
Drug: Regular 6-monthly
RxNorm normalized name: Insulina regular
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular 6-monthly anthelmintic treatment
Trial: 9626461
Drug: Etanidazole (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanidazole (dose levels between 3 and 5.5 g/m2/day, total doses of 12, 16, 20, and 22 g/m2)
Trial: 9626461
Drug: Etanidazole (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanidazole (16 g/m2 dose level)
Trial: 9626461
Drug: High-dose ICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ICE (ifosfamide, carboplatin, etoposide)
Trial: 3144513
Drug: Budesonide (one-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (one-dose pretreatment)
Trial: 3144513
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (one-dose pretreatment)
Trial: 3144513
Drug: Terbutaline (one-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (one-dose pretreatment)
Trial: 23807156
Drug: Elvitegravir once
RxNorm normalized name: Elvitegravir
DrugBank: Elvitegravir (DB09101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Elvitegravir once daily
Trial: 20653670
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily)
Trial: 20653670
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily) + Placebo
Trial: 20653670
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily) in patients with pre-treatment scores >18
Trial: 20653670
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily) in second phase
Trial: 20653670
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg once daily) + Placebo in second phase
Trial: 18089770
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous doses of PC-SOD (40-160 mg)
Trial: 18089770
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of PC-SOD (80 mg for 7 days)
Trial: 18089770
Drug: Single 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 80 mg dose of PC-SOD
Trial: 9186076
Drug: Fosinopril and
RxNorm normalized name: fosinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril and Lisinopril (combined with furosemide)
Trial: 9186076
Drug: Fosinopril and
RxNorm normalized name: fosinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril and Lisinopril (in blacks)
Trial: 9186076
Drug: Fosinopril and
RxNorm normalized name: fosinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril and Lisinopril (in nonblacks)
Trial: 3911700
Drug: Oxycone-papaverine 5+50
RxNorm normalized name: papaverine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycone-papaverine 5+50 mg
Trial: 29762909
Drug: Dichlorphenamide, single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichlorphenamide, single doses of 25‐400 mg followed by 50‐800 mg/day for 10 doses.
Trial: 29762909
Drug: Dichlorphenamide, up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichlorphenamide, up to 28 titrated doses from 100‐800 mg/day (Cohort F).
Trial: 29762909
Drug: Cohorts A,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts A, B, and C (doses of 25-400 mg and 50-800 mg/day).
Trial: 27063319
Drug: Remifentanil at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil at effect‐site concentration of 1.5 ng/mL
Trial: 24486089
Drug: Telaprevir plus
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir plus peginterferon/ribavirin therapy
Trial: 22482335
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid 5 mg daily for 8 weeks
Trial: 20579335
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behaviour therapy (CBT) for anxiety disorders
Trial: 20579335
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behaviour therapy (CBT) for depression
Trial: 20579335
Drug: Brief cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief cognitive behaviour therapy (CBT) for mixed anxiety and depression
Trial: 20579335
Drug: Problem solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem solving therapy (PST) for depression and mixed anxiety and depression
Trial: 17270528
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive drugs (control)
Trial: 9109134
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily ceftriaxone plus amikacin
Trial: 9109134
Drug: Three times
RxNorm normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three times daily ceftazidime plus amikacin
Trial: 22048173
Drug: HPV-16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 vaccine (Cervarix®, GlaxoSmithKline Biologicals, Months 0, 1, 6)
Trial: 22048173
Drug: HPV-6/11/16/18 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-6/11/16/18 vaccine (Gardasil® Merck & Co., Inc., Months 0, 2, 6)
Trial: 8704686
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) therapy
Trial: 1388172
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment methods for lateral epicondylitis
Trial: 1388172
Drug: Placebo effect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo effect of all treatments
Trial: 24293167
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C (2 g before surgery and 500 mg twice daily for 5 days after surgery)
Trial: 24293167
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin C
Trial: 23733308
Drug: SOC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC plus mefloquine (250 mg for 3 days, then 250 mg weekly)
Trial: 20886185
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg BID starting 12-24 hours postoperatively)
Trial: 20886185
Drug: TAK-442 10
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 10 mg BID
Trial: 20886185
Drug: TAK-442 20
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 20 mg BID
Trial: 20886185
Drug: TAK-442 40
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 40 mg QD
Trial: 20886185
Drug: TAK-442 40
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 40 mg BID
Trial: 20886185
Drug: TAK-442 80
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 80 mg QD
Trial: 20886185
Drug: TAK-442 80
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 80 mg BID
Trial: 20886185
Drug: TAK-442 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-442 (all doses except 10 and 20 mg BID)
Trial: 18634152
Drug: High-dose iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose iloprost (up to 2 ng/kg body weight per minute)
Trial: 18634152
Drug: Low-dose iloprost
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iloprost (0.5 ng/kg body weight per minute)
Trial: 18634152
Drug: Both high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both high-dose and low-dose iloprost
Trial: 18634152
Drug: High-dose iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose iloprost
Trial: 18634152
Drug: Low-dose iloprost
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose iloprost
Trial: 14637388
Drug: Tumour marker
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumour marker guided treatment (salvage treatment)
Trial: 14637388
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (after radiological confirmation of metastases)
Trial: 23414120
Drug: Erythropoietin intravenous
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin intravenous (EIV) group
Trial: 23414120
Drug: Erythropoietin subcutaneous
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin subcutaneous (ESC) group
Trial: 21719898
Drug: Yogurt supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt supplement (YOG; n = 15)
Trial: 17209212
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplements for cancer prevention
Trial: 17209212
Drug: Nutritional agents
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional agents
Trial: 16281923
Drug: Valacyclovir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir treatment
Trial: 29425398
Drug: Child therapy
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Child therapy
Trial: 12049443
Drug: Combined child
RxNorm normalized name: Senna-Relief Childs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined child therapy and parent/teacher training
Trial: 9855591
Drug: Intravenous opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opioids (meperidine)
Trial: 9855591
Drug: Intravenous opioids
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opioids (compliant patients)
Trial: 1976938
Drug: Grapefruit Pill
RxNorm normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit Pill
Trial: 1976938
Drug: Natural Vitality
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural Vitality pill
Trial: 24646
Drug: Lorazepam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (mean dose of approximately 3 mg on a b.i.d. regimen)
Trial: 28391283
Drug: Soy drink
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy drink (250 mL, 12 mg isoflavones)
Trial: 28391283
Drug: Decaffeinated black
RxNorm normalized name: acid black 52
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated black tea (300 mL, 67 mg catechins)
Trial: 28391283
Drug: Water (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water (300 mL, control)
Trial: 25811794
Drug: Gastroretentive gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gastroretentive gabapentin (G-GR) 1800 mg once-daily
Trial: 23902431
Drug: Cynatine(®) HNS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cynatine(®) HNS (500 mg keratin plus vitamins and minerals)